Catalyst Pharmaceuticals, Inc. announced the appointment of Ms. Tamar Thompson to the company's board of directors (‘Board'), effective on May 25, 2023. Ms. Thompson has more than twenty years of leadership experience in health care, health policy strategy, government affairs, and market access, with a diverse background across multiple healthcare sectors and therapeutic categories, including rare diseases, with a focus on developing strategic and tactical recommendations to ensure optimal reimbursement and market access for rare disease products. Ms. Thompson currently serves as Vice President, Head of Global Corporate Affairs for Alexion Pharmaceutical, AstraZeneca Rare Diseases.

Prior to joining Alexion, Ms. Thompson served as Executive Director, State Government Affairs and Federal Policy for Bristol-Myers Squibb Company. Prior to joining Bristol Myers Squibb, she served as a strategic policy advisor and consultant for various governmental affairs firms based in Washington, D.C. Ms. Thompson received a Master of Science in Health Sciences with a concentration in Public Health from Trident University in Cypress, California, and currently serves on the Board of Directors of Avidity Biosciences.